Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges

MET exon 14 skipping mutation (MET∆ex14) is present about 3% of non-small cell lung cancers (NSCLCs). NSCLC patients with MET∆ex14 are characterized by an average age of over 70 years at diagnosis, a smoking history and a higher frequency in pleomorphic carcinoma and adenosquamous cell carcinoma tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujino, Toshio, Suda, Kenichi, Mitsudomi, Tetsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8290191/
https://www.ncbi.nlm.nih.gov/pubmed/34295201
http://dx.doi.org/10.2147/LCTT.S269307

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8290191/
https://www.ncbi.nlm.nih.gov/pubmed/34295201
http://dx.doi.org/10.2147/LCTT.S269307

Ejemplares similares